InsightfulValue
← Home

Stock Swings

Price Drops

No drop incidents

Price Hikes

+11.16% closed: 2024-11-13

Bristol Myers Squibb (BMY) stock rocketed Monday after AbbVie’s (ABBV) experimental schizophrenia treatment failed in a pair of midstage studies. The news bolsters Bristol Myers’ new schizophrenia treatment, Cobenfy

+5.36% closed: 2024-11-02

The Drugmaker Hiked Guidance After Sales Beat. stock rose after the pharmaceutical company lifted its 2024 outlook on the back of strong quarterly sales of both legacy and newer drugs, despite generic competition and loss of exclusivity for some of its medicines

Wait! There's more — sign up for free or log in

© 2024 - 2025 InsightfulValue.com. All rights reserved. Legal